One of Af­fimed’s new glass slip­pers cracks as a dead­ly in­ci­dent forces halt to PhI can­cer tri­als

Af­fimed’s Cin­derel­la sto­ry has tak­en a dead­ly twist.

Just a few weeks af­ter sign­ing Genen­tech on to the plat­form for a col­lab­o­ra­tion us­ing its NK cell tech for guid­ing an im­mune re­sponse against can­cer, re­searchers for the biotech $AFMD have waved back pa­tients in a Phase I pro­gram for their CD19/CD3-tar­get­ing T cell en­gager AFM11 af­ter the death of one pa­tient and a life-threat­en­ing re­ac­tion in two oth­ers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER